Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil ON: Long Term Extension Study of Spesolimab in GPP
NCT03886246Phase 2Active, not recruiting
- Sponsor
- LEO Pharma
- Start
- May 2019
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 2 trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by LEO Pharma. Started May 2019; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT03886246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886246.